Effect of synergistic interaction between abnormal adiposity-related metabolism and prediabetes on microalbuminuria in the general population

Jong Wook Choi*, Il Hwan Oh*, Chang Hwa Lee*, Joon-Sung Park*

Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

These authors contributed equally to this work.
* sjipoon@hanyang.ac.kr (JSP); changhwa@hanyang.ac.kr (CHL)

Abstract

Central obesity and related metabolic components are important risks for microalbuminuria. To describe the effects of interactions between central obesity and related metabolic components on microalbuminuria, we conducted a nation-wide, population-based interaction analysis using cardio-metabolic index (CMI) as a candidate indicator of central obesity and related abnormal lipid metabolism. We recruited native Koreans aged 20 years or older with no medical illness. A total of 5398 participants were divided into quintiles according to CMI with sex as a covariate factor. Participants in the highest CMI quintile had elevated blood pressure (BP), increased glycemic exposure, poor lipid profile, and increased urine albumin-to-creatinine ratio compared to other lower quintiles. Multiple logistic regression models adjusted for age, sex, systolic BP, and diastolic BP showed that CMI had an independent association with increased glycemic exposure and increased urine albumin-to-creatinine ratio. Our interaction analysis revealed a significant interaction between the highest CMI quintile and prediabetes with an increased risk of microalbuminuria (adjusted RERI = 0.473, 95% CI = 0.464–0.482; adjusted AP = 0.276, 95% CI = 0.156–0.395; adjusted SI = 2.952, 95% CI = 1.234–4.670). Our findings suggest a significant association between central obesity-related abnormal lipid metabolism and prediabetes, and their interaction may exert a synergistic effect on renal vascular endothelial dysfunction even before the appearance of full-blown diabetes mellitus. To confirm these findings, large population-based prospective studies are needed.

Introduction

Central obesity and related abnormal lipid metabolism are main components of metabolic syndrome, which is a major public health and economic problem on the global scale [1]. Accumulating evidence indicates that the copious release of free fatty acids and various pro-inflammatory cytokines/adipokines from dysfunctional adipose tissue plays a central role in the development of low-grade systemic inflammation and metabolic complications in patients with visceral obesity [2]. Accurate measurement of central obesity is critical to assess the...
severity of its metabolic disturbances and to prevent irreversible metabolic disorders. Recently, the cardio-metabolic index (CMI), simply calculated as the product of waist-to-height ratio (WHtR) and triglycerides (TG) to high-density lipoprotein (HDL) cholesterol ratio, was introduced as a possible clinical indicator reflecting central obesity and related abnormal lipid metabolism; CMI has been shown to describe the risk of diabetes in the general population and also had an association with progression of atherosclerosis in patients with peripheral arterial disease [3, 4], suggesting that CMI may be a useful marker for endovascular damage. However, little is known about its role in estimating the negative effects of central obesity-related abnormal lipid metabolism on kidney function.

Prediabetes refers to a plasma glucose level above the normal range but not high enough to meet the diagnostic criteria for diabetes [5]. Previous epidemiological studies have demonstrated that increased glycemic exposure is independently associated with glomerular hyperfiltration, vascular endothelial dysfunction, and hyperglycemia-related metabolic disturbance, and these conditions are strongly linked to the development of chronic kidney disease as well as cardiovascular disease [6–8]. Recently, some authors have argued that various forms of vascular complications associated with diabetes may be prominent in subjects with prediabetes [9], suggesting that mild hyperglycemia itself may be a leading cause of vascular endothelial dysfunction, independent of central obesity and related abnormal lipid metabolism.

Microalbuminuria indicates a small increase in the leakage of albumin into urine, but it may implicate the presence of glomerular filtration barrier dysfunction, a significant feature of microvascular complication in patients with diabetes [10]. It is widely accepted that the development of vascular endothelial damage is independently associated with central obesity-related abnormal lipid metabolism as well as hyperglycemia-related metabolic disturbances, and there is close link between them [11, 12]. However, there is little clinical evidence of their interaction, especially in the general population. Thus, to directly address this relationship, we conducted an interaction analysis using CMI as a candidate indicator of abnormal central obesity-related lipid metabolism.

Subjects and methods
Study population
All data were collected from public-use data sets from the Korean National Health and Nutrition Examination Survey (KNHANES) conducted by the Korea Centers for Disease Control and Prevention (KCDC) among non-institutionalized Korean civilians between 2013 and 2014. All participants were volunteers, and all provided written informed consent before enrollment in the study. Their records, except for the date of the survey, were anonymized prior to analysis. The study protocol was approved by the Institutional Review Board (IRB) of the KCDC (IRB: 2013-07CON-03-4C, 2013-12EXP-03-5C).

A total of 15568 individuals participated in the KHANES 2013–2014. Individuals were excluded from the present analysis for any of the following reasons: (1) incomplete anthropometric or laboratory data, (2) < 20 years of age, (3) pregnancy, (4) a history of medical problems, such as diabetes, hypertension, cardiovascular diseases, and malignancies, (5) estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², or (6) urine albumin-to-creatinine ratio (UACR) > 300 mg/g creatinine. The final 5398 participants were divided into quintiles according to CMI and were categorized by sex (S1 Fig).

Anthropometric and clinical measurements
Anthropometric measurements were performed by well-trained examiners. Participants wore a lightweight gown or underwear. Height (Ht) was measured to the nearest 0.1 cm using a
portable stadiometer (Seriter, Bismarck, ND). Weight was measured to the nearest 0.1 kg on a calibrated balance-beam scale (Giant-150N; Hana, Seoul, Korea). Waist circumference (WC) was measured using a flexible tape at the narrowest point between the lowest border of the rib cage and the uppermost lateral border of the iliac crest at the end of normal expiration. BMI was calculated as weight in kilograms divided by square of the height in meters. WHtR was calculated as WC divided by height.

Blood pressure (BP) was measured three times using a mercury sphygmomanometer (Baumanometer; Baum, Copiague, NY) while subjects were in a sitting position following a 5-minute rest period. The average values of the three recorded systolic and diastolic BPs were used in the analysis.

Laboratory tests
Venous blood samples were collected after 8 h overnight fasting. Fasting plasma concentrations of glucose, low-density lipoprotein cholesterol, HDL cholesterol, and TG were determined using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan). Glycated hemoglobin (HbA1c) levels were determined using high-performance liquid chromatography with an automated HLC-723G7 analyzer (Tosoh Corporation, Tokyo, Japan). Serum creatinine levels were measured colorimetrically (Hitachi Automatic Analyzer 7600), and eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) [13]. To obtain the UACR, urinary albumin was measured in spot urine using the immunoturbidimetric method, and urinary creatinine was measured using the colorimetric method.

Definitions
According to the 2016 American Diabetes Association standards of medical care [14], prediabetes was defined as a fasting glucose between 100 and 125 mg/dl or HbA1c in the range 5.7 to 6.4% without the use of hypoglycemic medications. According to the KDIGO 2012 Clinical Practice Guidelines [15], participants with microalbuminuria were defined as those with a UACR between 30 and 300 mg/g creatinine, and participants with mild decline of kidney function were defined as those with an eGFR between 60 and 89 mL/min/1.73 m$^2$.

Statistical analysis
All data, including socio-demographic information, medical conditions, anthropometric and clinical measurements, and laboratory results, were presented as mean ± SE or frequency (and proportion). The normality of the distribution of parameters was analyzed by the Kolmogorov-Smirnov test. Data were analyzed using sampling weights to account for multistage and stratified sampling. The generalized linear model was used to compare quantitative variables, and the Chi-square test was used to compare proportions for categorical variables. Linear regression analysis was used to assess the relationships between potential predictor variables and CMI. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated in multiple logistic regression models according to the presence of microalbuminuria (case vs. control). Age and sex were initially adjusted as covariates in both linear regression and multiple logistic regression models. Further adjustment was made for the covariates that were significant in the first analyses. Other clinical and laboratory variables were evaluated as predictors using regression analyses.

Receiver operating characteristic (ROC) curves were used to compare the predictive capacity of CMI and anthropometric indices of central obesity on microalbuminuria. The nonparametric method of Delong was used to compare the areas under the ROC curves (AUCs) [16].
A biological interactive effect between candidate risk factors on dependent variables was evaluated on both a multiplicative scale and additive scales using logistic regression analysis [17]. The interaction analysis based on the multiplicative scale was performed by comparing participants in the highest CMI quintile, participants with prediabetes, or participants with both prediabetes and participants in the first 4 quintiles with normal glycemic exposure. The interaction based on the additive scale was evaluated by 3 indices: RERI, the relative excess risk due to the interaction; AP, the attributable proportion due to the interaction; and SI, the additive interaction index of synergy [18]. RERI is the excess risk due to the interaction relative to the risk without exposure. AP refers to the attributable proportion of disease that is due to the interaction among individuals with both exposures. SI is the excess risk from both exposures when there is an additive interaction, relative to the risk from both exposures without interaction. If the 95% CI of RERI and AP included 0, and the 95% CI of S contained 1, it was interpreted that there was no additive interaction between candidate variables.

A two-tailed P < 0.01 was considered statistically significant. Statistical Analysis Software, version 9.4 (SAS Institute Inc., Cary, NC, USA), was used for all analyses.

Results

Baseline characteristics

The participants (n = 5398) comprised 2186 men and 3212 women with a mean age of 39.4 ± 0.3 years. They were divided into quintiles according to CMI and were categorized according to sex. Participants in the highest quintile were older and more hypertensive than those in the other quintiles, and they were more likely to have increased glycemic exposure, worse lipid profiles, and poor kidney function. There were no differences in other baseline characteristics across CMI quintiles (Table 1).

Table 1. General characteristics of the study cohort grouped according to cardio-metabolic index (CMI).

| Variables (n = 1080) | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | P |
|---------------------|------------|------------|------------|------------|------------|---|
| Age (years)         | 35.2 ± 0.4 | 38.8 ± 0.4 | 40.7 ± 0.5 | 43.6 ± 0.5 | 44.6 ± 0.5 | <0.0001 |
| Sex (% male)        | 438 (41)   | 436 (40)   | 438 (41)   | 436 (40)   | 438 (41)   | 0.9726 |
| Systolic BP (mmHg)  | 107.4 ± 0.4| 108.5 ± 0.4| 110.2 ± 0.4| 111.6 ± 0.4| 114.4 ± 0.4| <0.0001 |
| Waist circumference (cm) | 72.5 ± 0.3 | 76.3 ± 0.3 | 78.8 ± 0.3 | 81.9 ± 0.3 | 85.4 ± 0.3 | <0.0001 |
| eGFR* (mL/min/1.73 m²) | 105.5 ± 0.5 | 102.4 ± 0.4 | 100.7 ± 0.5 | 99.3 ± 0.5 | 99.6 ± 0.5 | 0.0002 |
| Hemoglobin (g/dL)   | 14.09 ± 0.05| 14.09 ± 0.06| 14.28 ± 0.06| 14.32 ± 0.05| 14.49 ± 0.05| <0.0001 |
| Triglycerides (mg/dL)| 53.2 ± 0.5 | 78.4 ± 0.7 | 103.3 ± 1.0 | 137.9 ± 1.4 | 261.0 ± 5.4 | <0.0001 |
| HDL-cholesterol (mg/dL) | 66.4 ± 0.4 | 57.4 ± 0.4 | 53.0 ± 0.3 | 48.6 ± 0.3 | 42.8 ± 0.3 | <0.0001 |
| LDL-cholesterol (mg/dL) | 98.8 ± 0.9 | 107.4 ± 1.0 | 108.9 ± 6.8 | 124.0 ± 4.2 | 118.4 ± 1.6 | <0.0001 |
| 25-Vitamin D (ng/mL) | 16.1 ± 0.4 | 16.0 ± 0.3 | 16.3 ± 0.3 | 16.2 ± 0.4 | 15.8 ± 0.4 | 0.8194 |
| Log-UACR (log mg/g Cr) | 1.30 ± 0.04 | 1.13 ± 0.04 | 1.26 ± 0.04 | 1.25 ± 0.04 | 1.44 ± 0.05 | 0.0093 |

Results are expressed as mean ± SD or frequency (and proportion). BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Log-UACR, log-transformed urine albumin/creatinine ratio; Cr, creatinine.

*estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

https://doi.org/10.1371/journal.pone.0180924.t001
The relationships between CMI, kidney function, and other related risk factors

We performed linear regression analysis with age and sex as covariates to assess the relationships between CMI and other baseline characteristics related to kidney function. As shown in S1 Table, we found that CMI had a significant relationship with important components of metabolic syndrome including systolic BP, diastolic BP, glycemic exposure, dyslipidemia, and central obesity.

Association of CMI with microalbuminuria

We performed multiple logistic regression models to quantify the associations between CMI and other candidate predictors for kidney disease. First, we found that there was a significant association between CMI and prediabetes in this population (adjusted OR = 1.080, 95% CI = 1.021–1.142, Table 2). Furthermore, our logistic models demonstrated that CMI also had an independent association with microalbuminuria (crude OR = 1.074, 95% CI = 1.006–1.145) regardless of age and sex, and further adjustment for age, sex, systolic BP, and diastolic BP did not attenuate this association (adjusted OR = 1.075, 95% CI = 1.001–1.154, Table 3). However, we could not observe an independent association between CMI and mild declined kidney function (S2 Table).

To obtain predictive values between CMI and conventional anthropometric indices of central obesity for microalbuminuria, we created receiver operating characteristic (ROC) curves by performing a logistic regression model with age, sex, systolic BP, and diastolic BP as covariates.

### Table 2. Multivariable logistic regression for prediabetes*.

| Variable                      | Crude OR 95% CI | Model I OR 95% CI | Model II OR 95% CI | Model III OR 95% CI |
|-------------------------------|----------------|------------------|--------------------|---------------------|
| Age (years)                   | 1.054 1.049–1.060 | 1.015 1.009–1.022 | 1.021 1.011–1.030 |                    |
| Female (vs. male)             | 0.681 0.601–0.772 |                  |                    |                    |
| Smoker (vs. non-smoker)       | 1.263 1.081–1.475 | 1.027–1.044      | 1.021 1.011–1.030 |                    |
| Systolic BP (mmHg)            | 1.033 1.026–1.039 | 1.015 1.009–1.022 |                    |                    |
| Diastolic BP (mmHg)           | 1.035 1.027–1.044 | 1.021 1.011–1.030 |                    |                    |
| Body mass index (kg/m²)       | 1.139 1.117–1.162 | 1.120 1.098–1.142 | 1.111 1.089–1.134 |                    |
| Waist circumference (cm)      | 1.056 1.048–1.063 | 1.045 1.037–1.053 | 1.402 1.034–1.050 |                    |
| eGFR (mL/min/1.73 m²)         | 0.965 0.961–0.969 | 0.996 0.990–1.002 |                    |                    |
| Hemoglobin (g/dL)             | 1.018 0.978–1.060 |                  |                    |                    |
| Fasting glucose (mg/dL)       | 1.193 1.178–1.208 | 1.177 1.161–1.193 | 1.177 1.161–1.196 | 1.173 1.156–1.189 |
| Hemoglobin A1c (%)            | 999.9 999.9–999.9 | 999.9 999.9–999.9 | 999.9 999.9–999.9 | 999.9 999.9–999.9 |
| Triglycerides (mg/dL)         | 1.003 1.003–1.004 | 1.002 1.002–1.003 | 1.002 1.001–1.003 | 1.001 1.000–1.002 |
| HDL-cholesterol (mg/dL)       | 0.976 0.971.981 | 0.984 0.978–0.990 | 0.985 0.979–0.990 | 0.993 0.987–0.999 |
| LDL-cholesterol (mg/dL)       | 1.005 1.000–1.011 | 1.004 0.998–1.009 |                    |                    |
| CMI                           | 1.312 1.221–1.411 | 1.194 1.121–1.273 | 1.174 1.105–1.248 | 1.080 1.021–1.142 |
| 25-Vitamin D (ng/mL)          | 1.034 1.018–1.049 | 1.002 0.985–1.019 |                    |                    |
| UACR (mg/g creatinine)        | 1.006 1.001–1.010 | 1.004 1.000–1.008 | 1.003 0.999–1.007 |                    |

*Defined as fasting glucose between 100 and 125 or hemoglobin A1c between 5.7 and 6.4%.

Model I, adjusted for age and sex

Model II, adjusted for age, sex, systolic BP, and diastolic BP.

Model III, adjusted for age, sex, systolic BP, diastolic BP, body mass index, and waist circumference.

OR, odd ratio; CI, confidence interval; Log-UACR, log-transformed urine albumin-to-creatinine ratio.

https://doi.org/10.1371/journal.pone.0180924.t002
covariates and compared the AUCs (Fig 1). Compared with WC (AUC = 0.5199, 95% CI = 0.4716–0.5681), CMI (AUC = 0.5523, 95% CI = 0.5069–0.5977, P = 0.0622) and BMI (AUC = 0.5223, 95% CI = 0.4732–0.5713, P = 0.6369) had higher predictive values for microalbuminuria, but the difference between CMI and WC was marginal.

To examine the interactive effects between central obesity-related abnormal lipid metabolism and increased glycemic exposure on kidney dysfunction, we performed multiplicative and additive interaction analyses. As shown in Table 4, compared with participants in the first 4 quintiles without prediabetes, participants with just prediabetes or those in the highest quintile had no significant risk for microalbuminuria after adjustment for age, sex, systolic BP, and diastolic BP, and the adjusted ORs were 1.324 (95% CI = 0.716–2.449; first 4 quintiles only) and 1.001 (95% CI = 0.665–1.525; pre-diabetes only). In contrast, participants in the highest quintile with prediabetes had a significantly increased risk for microalbuminuria (crude OR = 2.676, 95% CI = 1.621–4.416), and adjustment for age, sex, systolic BP, and diastolic BP did not affect this multiplicative interaction (adjusted OR = 2.008, 95% CI = 1.233–3.271).

In additive interaction analysis (Table 5), we found that there was increased risk of microalbuminuria in participants in the highest quintile with prediabetes, attributed to the interaction between them, even after adjustment for age, sex, systolic BP, and diastolic BP (adjusted AP = 27.6%, 95% CI = 0.156–0.395). Furthermore, the interaction index for synergy was 2.952 (95% CI = 1.234–4.670), suggesting that there was a synergistic interaction between central obesity-related abnormal lipid metabolism and increased glycemic exposure in the risk of microalbuminuria, even before the appearance of overt hypertension and diabetes.
Discussion

This study provides comprehensive information on the performance of CMI as a surrogate indicator for central obesity-related abnormal lipid metabolism with respect to kidney function. We demonstrated that there is a positive synergistic interactive relationship between CMI and mild hyperglycemia on the risk of microalbuminuria in the general population. These results indicate that central obesity-related abnormal lipid metabolism and its metabolic

Fig 1. Receiver-operating characteristic (ROC) curves representing the prediction capacity of risk for (B) microalbuminuria. Compared with WC (AUC* = 0.5199, 95% CI* = 0.4716–0.5681), CMI (AUC* = 0.5523, 95% CI* = 0.5069–0.5977, P* = 0.0662) and BMI (AUC* = 0.5223, 95% CI* = 0.4732–0.5713, P* = 0.6369) have better precision in predicting microalbuminuria, but the difference was not statistically significant. BMI; body mass index; WC, waist circumference; AUC, area under the curve; CI, confidence interval. *calculated by logistic regression analysis using age, sex, systolic BP, and diastolic BP as covariates.

https://doi.org/10.1371/journal.pone.0180924.g001

Table 4. Interactive effect analysis of CMI quintile and prediabetes on microalbuminuria.

| Categories    | CMI quintile | Unadjusted | Adjusted* |
|---------------|--------------|------------|-----------|
| Prediabetes   |              | OR 95% CI  | OR 95% CI |
| (-)           | 1–4          | 1 (reference)| 1 (reference) |
| (-)           | 5            | 1.601      | 1.324     | 0.716–2.449 |
| (+)           | 1–4          | 1.147      | 1.001     | 0.665–1.525 |
| (+)           | 5            | 2.676      | 2.008     | 1.233–3.271 |

* adjusted for age, sex, systolic BP, and diastolic BP.

https://doi.org/10.1371/journal.pone.0180924.t004
interaction with glycemic exposure may be one of the leading causes of vascular endothelial dysfunction and kidney disease, even before the diagnosis of diabetes and hypertension.

In this study, we used CMI as a possible indicator of central obesity-related abnormal lipid metabolism. Our logistic regression models and ROC curve analysis revealed that CMI was independently associated with the risk of microalbuminuria. Moreover, CMI was more precise than conventional anthropometric indices in estimating the negative effects of central obesity-related abnormal lipid metabolism on kidney dysfunction. Currently, BMI and WC are widely used anthropometric indices in estimating body fat mass, but they have some limitations. BMI for measurement of obesity is not accurate to assess central adiposity because BMI is likely to overestimate obesity in adults with edema, a large amount of muscle mass, and/or peripheral fat distribution [19]. On the other hand, WC is accepted as a key metric of central obesity that can anticipate the risk of diabetes, hypertension, and cardiovascular disease in the general population [20]. However, enlarged WC could be due to abdominal subcutaneous or visceral adipose depots [21]. Furthermore, neither BMI nor WC can fully reflect abnormal lipid profiles. Thus, there is need for a more accurate clinical indicator to evaluate the systemic effect of metabolic disturbance, and CMI may be this indicator, based on the following reasons. WHtR may be better than WC or BMI as an obesity indicator for prediction of metabolic effects on the body, including the kidney [22–25], and the TG/HDL cholesterol ratio may be better than other lipid-related ratios at predicting kidney function [26]. Furthermore, recent studies have demonstrated that obesity-related kidney disease is more related to circulating TG level and renal deposition of lipids than to body weight itself [27]. These findings suggest that CMI could be a more sensitive indicator of metabolic disturbance in kidney disease.

Our results demonstrated that CMI was strongly related to increased glycemic exposure and poor lipid profiles and was independently associated with microalbuminuria, an important clinical indicator of vascular endothelial dysfunction. Non-specific inflammatory responses are accepted as a key mechanism involved in central obesity-related target organ manifestations [28]. Previous experimental research has demonstrated that various pro-inflammatory cytokines and hormones secreted from dysregulated adipocytes and macrophages within visceral fat may lead to low-grade systemic inflammation, insulin resistance, dyslipidemia, and/or increased synthesis of vasoactive and fibrogenic substances, and their complicated interactions may have a negative influence on vascular endothelial cells and cause impairment of kidney function [29–33]. However, there is limited clinical evidence of these pathologic situations. Our study adds clinical evidence of the pathologic effect of central obesity on the vascular endothelium in company with abnormal lipid profiles and increased glycemic exposure.

Microalbuminuria is the end result of complex interactions between endocrine, metabolic, and hemodynamic factors [34]. Previous epidemiologic studies have demonstrated that,
compared with healthy subjects, patients with prediabetes had increased UACR, which was closely related with progression to type 2 diabetes [35, 36]. Recently, some authors also argued that central obesity and related abnormal lipid metabolism were significantly associated with increased urinary excretion of albumin, regardless of glycemic status [37–40]. However, epidemiologic evidence of the interaction between central obesity-related abnormal lipid metabolism and dysglycemia on the development of microalbuminuria is still very limited. Our results indicate that the additive synergistic interaction between CMI and prediabetes may exert a negative effect on vascular endothelial function in the kidney.

However, we could not observe an independent association between CMI and mild decline in kidney function. This is inconsistent with other reports showing that there was a strong relationship between increased anthropometric indices and progression of kidney disease [41]. A possible explanation for this discrepancy is that this study was limited by its cross-sectional study design, which made it difficult to efficiently demonstrate the long-term harmful effects of metabolic disturbances on the changes in kidney function. Another possible explanation is that CMI may be a more reliable indicator for negative consequences of central obesity-related abnormal lipid metabolism on vascular endothelial function rather than irreversible progression to renal fibrogenesis. Thus, further studies are needed to resolve these issues.

There were several limitations to our study. First, because a very small number of participants had UACR > 300 mg/g creatinine, we could not include these participants in the study. This limitation made it impossible to investigate a relationship between metabolic disturbance and overt proteinuria. Second, the development of vascular endothelial dysfunction may have been influenced by a wide variety of factors. Because of the limitations of the study design, we could not adjust for many factors other than age, sex, and BP. Third, because of the self-reporting of medical history, medication, and use of tobacco and alcohol, a social-desirability bias cannot be ruled out. These biases might have been responsible for the results and conclusions that conflict with previous research. Finally, participants may have forgotten to report relevant details.

The results of the present study indicate that CMI could be valuable for predicting renal manifestations associated with metabolic disturbances. Furthermore, a synergistic interaction between central obesity-related abnormal lipid metabolism and prediabetes may be closely related to increased risk of microalbuminuria. A large population-based prospective epidemiologic study is needed to confirm these findings.

Supporting information

S1 Fig. Flow chart of the study group enrollment process. KHANES, The Korean National Health and Nutritional Examination Survey; Q, cardio-metabolic index (CMI) quintile. (TIF)

S1 Table. Linear regression for CMI. Model I, adjusted for age and sex. (DOCX)

S2 Table. Multivariable logistic regression for early decreased kidney function. * defined as eGFR between 60 and 89 mL/min/1.73 m². Model I, adjusted for age and sex. (DOCX)

Author Contributions

Conceptualization: Chang Hwa Lee, Joon-Sung Park.
Formal analysis: Jong Wook Choi, Joon-Sung Park.
Investigation: Chang Hwa Lee, Joon-Sung Park.
Methodology: Joon-Sung Park.
Project administration: Chang Hwa Lee, Joon-Sung Park.
Software: Joon-Sung Park.
Supervision: Chang Hwa Lee, Joon-Sung Park.
Visualization: Jong Wook Choi, Joon-Sung Park.
Writing – original draft: Jong Wook Choi, Il Hwan Oh, Joon-Sung Park.
Writing – review & editing: Chang Hwa Lee, Joon-Sung Park.

References
1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005; 366:1059–62. https://doi.org/10.1016/S0140-6736(05)67402-8 PMID: 16182882.
2. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15:6184–223. https://doi.org/10.3390/ijms15046184 PMID: 24733068.
3. Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015; 438:274–8. https://doi.org/10.1016/j.cca.2014.08.042 PMID: 25199852.
4. Wakabayashi I, Sotoda Y, Hirooka S, Orita H. Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clin Chim Acta. 2015; 446:231–6. https://doi.org/10.1016/j.cca.2015.04.020 PMID: 25920694.
5. Sorensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, et al. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. Circulation. 2016; 134:1339–52. https://doi.org/10.1161/CIRCULATIONAHA.116.023446 PMID: 27678264.
6. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012; 379:2279–90. https://doi.org/10.1016/S0140-6736(12)60283-9 PMID: 22683126.
7. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care. 2000; 23:1113–8. PMID: 10937507.
8. Grundy SM. Prediabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012; 59:635–43. https://doi.org/10.1016/j.jacc.2011.08.080 PMID: 22322078.
9. Shin DI, Seung KB, Yoon HE, Hwang BH, Seo SM, Shin SJ, et al. Microalbuminuria is independently associated with arterial stiffness and vascular inflammation but not with carotid intima-media thickness in patients with newly diagnosed type 2 diabetes or essential hypertension. J Korean Med Sci. 2013; 28:252–60. https://doi.org/10.3346/jkms.2013.28.2.252 PMID: 23400641.
10. Todd JN, Dahlstrom EH, Salem RM, Sandholm N, Forsblom C, McKnight AJ, et al. Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. Diabetes. 2015; 64:4238–46. https://doi.org/10.2337/db15-0254 PMID: 26307587.
11. Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013; 97:59–74. https://doi.org/10.1016/j.mcna.2012.10.010 PMID: 23290730.
12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2005; 142:417–26. PMID: 15805531.
13. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017; 40: S11–s24. https://doi.org/10.2337/dc17-S005 PMID: 27979889.
14. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158:825–30. https://doi.org/10.7326/0003-4819-159-11-201306040-00007 PMID: 23732715.
16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837–45. PMID: 3203132.

17. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011; 26:433–8. https://doi.org/10.1007/s10654-011-9554-9 PMID: 21344323.

18. Yang X, Zhao H, Sui Y, Ma RC, So WY, Ko GT, et al. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes. 2009; 58:1518–25. https://doi.org/10.2337/db09-0105 PMID: 19401427.

19. Agarwal R, Bills JE, Light RP. Diagnosing obesity by body mass index in chronic kidney disease: an explanation for the “obesity paradox?”. Hypertension. 2010; 56:893–900. https://doi.org/10.1161/HYPERTENSIONAHA.110.167264 PMID: 21344323.

20. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366:1640–9. https://doi.org/10.1016/S0140-6736(05)67663-5 PMID: 16271645.

21. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012; 126:1301–13. https://doi.org/10.1161/CIRCULATIONAHA.111.067264 PMID: 22949540.

22. Ashwell M, Lejeune S, McPherson K. Ratio of waist circumference to height may be better indicator of need for weight management. BMJ. 1996; 312:377. PMID: 8611847.

23. Chandie Shaw PK, Berger SP, Mallat M, Frolich M, Dekker FW, Rabelink TJ. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian subjects. Diabetes Care. 2007; 30:1840–4. https://doi.org/10.2337/dc07-0028 PMID: 17456841.

24. Du N, Peng H, Chao X, Zhang Q, Tian H, Li H. Interaction of obesity and central obesity on elevated urinary albumin-to-creatinine ratio. PLoS One. 2014; 9:e98926. https://doi.org/10.1371/journal.pone.0098926 PMID: 24892930.

25. Kodama S, Horikawa C, Fujihara K, Heianza Y, Hirasawa R, Yachi Y, et al. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis. Am J Epidemiol. 2012; 176:959–69. https://doi.org/10.1093/aje/kws172 PMID: 23144362.

26. Kim JY, Kang HT, Lee HR, Lee YJ, Shim JY. Comparison of lipid-related ratios for prediction of chronic kidney disease stage 3 or more in Korean adults. J Korean Med Sci. 2012; 27:1524–9. https://doi.org/10.3346/jkms.2012.27.12.1524 PMID: 23255852.

27. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis. 1992; 20:629–34. PMID: 1462993.

28. Ghiglotti G, Barisone C, Garibaldi S, Fabbri P, Brunelli C, Spallarossa P, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014; 37:1337–53. https://doi.org/10.1007/s10753-014-9914-1 PMID: 24823865.

29. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013; 3:957–76. https://doi.org/10.1002/cphy.c120028 PMID: 23720336.

30. Kurozumi A, Okada Y, Arao T, Tanaka Y. Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. Intern Med. 2016; 55:3091–5. https://doi.org/10.2169/internalmedicine.55.6940 PMID: 27803400.

31. Kim SH, Despres JP, Koh KK. Obesity and cardiovascular disease: friend or foe? Eur Heart J. 2016; 37:3560–8. https://doi.org/10.1093/eurheartj/ehv509 PMID: 26685971.

32. Wu CC, Liou HH, Su PF, Chang MY, Wang HH, Chen MJ, et al. Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant. 2011; 26:3689–95. https://doi.org/10.1093/ndt/gfr057 PMID: 21357211.

33. Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev. 2011; 7:41–9. PMID: 21067508.

34. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008; 51:714–25. https://doi.org/10.1007/s00125-008-0961-8 PMID: 18347777.

35. Bahar A, Makhlough A, Yousefi A, Kashfi Z, Abediankenari S. Correlation between prediabetes conditions and microalbuminuria. Nephronrol Mon. 2013; 5:741–4. https://doi.org/10.5812/nmonthly.7646 PMID: 23841037.

36. Dutta D, Choudhuri S, Mondal SA, Mukherjee S, Chowdhury S. Urinary albumin: creatinine ratio predicts prediabetes progression to diabetes and reversal to normoglycemia: role of associated insulin
resistance, inflammatory cytokines and low vitamin D. J Diabetes. 2014; 6:316–22. https://doi.org/10.1111/1753-0407.12112 PMID: 24251376.

37. Glastras SJ, Chen H, Teh R, McGrath RT, Chen J, Pollock CA, et al. Mouse Models of Diabetes, Obesity and Related Kidney Disease. PLoS One. 2016; 11:e0162131. https://doi.org/10.1371/journal.pone.0162131 PMID: 27579698.

38. Yoon SJ, Kim DH, Nam GE, Yoon YJ, Han KD, Jung DW, et al. Prevalence and control of hypertension and albuminuria in South Korea: focus on obesity and abdominal obesity in the Korean National Health and Nutrition Examination Survey, 2011–2012. PLoS One. 2014; 9:e111179. https://doi.org/10.1371/journal.pone.0111179 PMID: 25360593.

39. Lee YY, Yang CK, Weng YM, Chuang CH, Yu W, Chen JC, et al. All Components of Metabolic Syndrome Are Associated with Microalbuminuria in a Chinese Population. PLoS One. 2016; 11:e0157303. https://doi.org/10.1371/journal.pone.0157303 PMID: 27327443.

40. Lee IT, Wang CY, Huang CN, Fu CC, Sheu WH. High triglyceride-to-HDL cholesterol ratio associated with albuminuria in type 2 diabetic subjects. J Diabetes Complications. 2013; 27:243–7. https://doi.org/10.1016/j.jdiacomp.2012.11.004 PMID: 23276621.

41. He Y, Li F, Wang F, Ma X, Zhao X, Zeng Q. The association of chronic kidney disease and waist circumference and waist-to-height ratio in Chinese urban adults. Medicine (Baltimore). 2016; 95:e3769. https://doi.org/10.1097/md.0000000000003769 PMID: 27336864.